Cargando…
Survival of mice with NC carcinoma is unchanged by drugs that are thought to inhibit thromboxane synthesis or increase prostacyclin formation.
Mice transplanted with NC carcinoma were treated with the thromboxane synthetase inhibitor dazmegrel (UK38485) or with nafazatrom (BAY G 6575), a compound that is reported to increase prostacyclin formation. Some experiments included the cytotoxic drugs methotrexate and melphalan. The tumours were e...
Autores principales: | Stamford, I. F., Melhuish, P. B., Carroll, M. A., Corrigan, C. J., Patel, S., Bennett, A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1986
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001530/ https://www.ncbi.nlm.nih.gov/pubmed/3755610 |
Ejemplares similares
-
Prostacyclin and thromboxane in benign and malignant breast tumours.
por: Laekeman, G. M., et al.
Publicado: (1986) -
Prostacyclin, thromboxane and glomerular filtration rate are abnormal in sickle cell pregnancy
por: Obilade, Opeyemi Abayomi, et al.
Publicado: (2017) -
Differential effects of oral and transdermal menopausal hormone therapy on prostacyclin and thromboxane in platelets
por: Raz, Limor, et al.
Publicado: (2014) -
Prostacyclin and thromboxane in breast cancer: relationship between steroid receptor status and medroxyprogesterone acetate.
por: Aitokallio-Tallberg, A., et al.
Publicado: (1985) -
Elevated Ratio of Urinary Metabolites of Thromboxane and Prostacyclin Is Associated with Adverse Cardiovascular Events in ADAPT
por: Montine, Thomas J., et al.
Publicado: (2010)